Views & Analysis Nine for 2021: Addressing the pandemic legacy In this second 'Nine for 2021' article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: t
Views & Analysis Nine for 2021: The COVID-19 legacy In the first of a two part series, IQVIA's Sarah Rickwood covers nine key trends and events that will affect the global healthcare and pharmaceutical industries in 2021.
News BioNTech to buy rival mRNA firm CureVac for $1.25bn BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
